Research has provided more support for the idea that differences do exist between the sexes. Since 2001, the interest seems to have waned. Called pharmacokinetics, it is the study of what the body does to a drug, not what the drug does to the body.
Five years ago was prime time to explore the ways in which men and women react to certain drugs-research that has provided more support for the idea that differences do exist between the sexes. Since 2001, the interest seems to have waned. Called pharmacokinetics, it is the study of what the body does to a drug, not what the drug does to the body.
In 2001, The Institute of Medicine: published a report, "Exploring the Biological Contributions to Human Health; Does Sex Matter?" which says that sex must be considered in all aspects and at all levels of biomedical research because sex does matter.
Four of them-Posicor to treat hypertension, antihistamines Seldane and Hismanal, and Propulsid for gastrointestinal problems-indicated more adverse effects in women when the drugs were widely prescribed for both genders. The report hypothesized that "greater health risks for women may be due to physiological differences that make women differentially more susceptible to some drug-related health risks."
Seldane, Hismanal and Propulsid induced fatal cardiac arrhythmia in some women, perhaps because of a women's QT level, the time it takes for the heart to relax after it contracts when pumping out blood, while male sex hormones moderate the heart muscle's sensitivity to these drugs, says the GAO.
And of course, who could forget the hoopla in 1997 surrounding the combination of fenfluramine and phentermine-fen/phen-which posed serious health risks for women?
Research has exposed a variety of reasons for the differences in gender response to certain drugs, including lower body weights in women, differences in absorption, metabolizing and elimination of drugs by the body and the effects of liver enzymes and sex hormones. Among the results of these mechanisms are that often more serious side effects are suffered by women than men, more women develop life-threatening ventricular arrhythmia after taking a variety of drugs and women wake up from anesthesia faster than men.
In addition, women are consuming more medications than men, including herbal remedies, over-the-counter medications and vitamins.
Heidi Law, director of clinical programs for Costa Mesa, Calif.-based Prescription Solutions, a pharmacy benefits manager (PBM), says that gender differences in response to drugs are not a major issue for her organization. "It's not that we don't recognize that it exists," she says. "If the differences were that important, the FDA would have made some recommendations on dosing and labeled drugs accordingly. Gender, along with genetics, height and weight, age and whether a person smokes or consumes alcohol, is just one of many factors that affect the way people respond to drugs."
Law adds there is such a large therapeutic index-the ratio of the drug dose which produces an undesired effect to the dose which causes the desired effects used as a measure of the relative safety of the drug for a particular treatment-that there is no need to stipulate different dosing levels.
Although Prescriptions Solutions might not address gender differences related to drugs, it is concerned with developing health initiatives by gender, such as programs directed at women on hormone replacement therapy and osteoporosis and treatment of benign prostatic hyperplasia for men.
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
The deliberate disconnection of Change Healthcare to ring fence a cyberattack entered its seventh day today. Prescribers are finding ways to get pharmacy claims processed, and UnitedHealth Group says disruption to the dispensing of prescriptions has been minimal. But independent pharmacies want more information and protection from financial consequences from pharmacy benefit managers.
Read More